94268-29-8 Usage
Uses
Used in Pharmaceutical Industry:
4-(azetidin-3-yl)benzonitrile hcl is used as a modulator of leukotrienes for its potential therapeutic effects in treating inflammatory diseases. It modulates leukotrienes, which are important mediators of inflammation in the body.
Used in Respiratory Disease Treatment:
4-(azetidin-3-yl)benzonitrile hcl is used as a treatment for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) due to its ability to inhibit leukotriene production.
Research and Development:
4-(azetidin-3-yl)benzonitrile hcl is used in ongoing research for the development of new treatments for inflammatory conditions, as it may hold promise for the advancement of medical therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 94268-29-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,4,2,6 and 8 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 94268-29:
(7*9)+(6*4)+(5*2)+(4*6)+(3*8)+(2*2)+(1*9)=158
158 % 10 = 8
So 94268-29-8 is a valid CAS Registry Number.
94268-29-8Relevant academic research and scientific papers
NOVEL COMPOUNDS
-
Page/Page column 45, (2019/03/05)
The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF
-
Page/Page column 85; 86, (2015/07/07)
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
-
, (2014/01/18)
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.
